证券代码：832982 证券简称：锦波生物 公告编号：2025-096 山西锦波生物医药股份有限公司 第四届监事会第八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 8 月 9 日 2.会议召开地点：公司二楼会议室 3.会议召开方式：现场加通讯 4.发出监事会会议通知的时间和方式：2025 年 7 月 30 日以电话方式发出 5.会议主持人：监事会主席汤莉女士 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 0 人。 监事汤莉因出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司 2025 年半年度报告及摘要的议案》 1.议案内容： 根据《公司法》《公司章程》等的规定，公司已编制完成《山西锦波生物医 药股份有限公司 2 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-100 山西锦波生物医药股份有限公司 公司 2024 年年度权益分派方案为：以公司股权登记日总股本 88,511,800 股 为基数，向全体股东每 10 股转增 3 股，（其中以股票发行溢价形成的资本公积金 每 10 股转增 3 股，不需要纳税；以其他资本公积每 10 股转增 0 股，需要纳税）， 每 10 股派 20 元人民币现金。本次权益分派权益登记日为 2025 年 6 月 17 日，除 权除息日为 2025 年 6 月 18 日。 综上，监事会认为：鉴于公司 2024 年年度权益分派已实施完毕，根据公司 2025 年第一次临时股东会授权，公司将本激励计划股票期权的授予数量由 798,000 份调整为 1,037,400 份，行权价格由 276 元/份调整为 210.77 元/份。上述 事项符合《上市公司股权激励管理办法》《北京证券交易所股票上市规则》等法 律法规以及公司激励计划的相关规定，不存在损害公司及股东利益的情况。监事 会一致同意调整 2025 年股票期权激励计划行权价格及数量。 山西锦波生物医药股份有限公司 监事会 2025 年 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-095 山西锦波生物医药股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 8 月 9 日 2.会议召开地点：公司二楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 7 月 30 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：汤莉、于玉凤、何振瑞、薛芳琴、兰小宾 7.召开情况合法、合规、合章程性说明： 董事金雪坤、王玲玲、张金鑫、阎丽明、梁桐栋因出差或外地办公以通讯方 式参与表决。 二、议案审议情况 （一）审议通过《关于公司 2025 年半年度报告及摘要的议案》 1.议案内容： 根据《公司法》《公司章程》等的规定，公司已编制完成《山西锦波生物医 药股份有限公司 2025 年半年度报告》《山西锦波生物医药股份有限公司 2025 年 半 年 度 报 告 摘 要 》。 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-098 山西锦波生物医药股份有限公司 2025 年半年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 为合理回报股东，结合公司实际情况和经营发展需要，根据《公司法》《公 司章程》等的规定，公司拟定 2025 年半年度权益分派方案。 一、权益分派预案情况 根据公司2025年8月11日披露的2025年半年度报告（财务报告未经审计）， 截至 2025 年 6 月 30 日，上市公司合并报表未分配利润为 1,301,237,656.97 元， 母公司未分配利润为 1,385,550,465.62 元。 公司本次权益分派预案如下：公司目前总股本为 115,065,340 股，以未分配 利润向全体股东每 10 股派发现金红利 10 元（含税）。本次权益分派共预计派发 现金红利 115,065,340 元。 公司将以权益分派实施时股权登记日应分配股数为基数，如股权登记日应分 配股数与目前预计不一致的，公司将维持分派比例不变，并相应调整 ...

证券之星消息，8月11日医疗美容板块较上一交易日上涨1.64%，爱美客领涨。当日上证指数报收于 3647.55，上涨0.34%。深证成指报收于11291.43，上涨1.46%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 300896 爱美客 | 731.91万 | 1.53% | 386.10万 | 0.81% | -1118.02万 | -2.34% | | 000615 *ST美谷 | -559.58万 | -20.32% | 148.36万 | 5.39% | 411.22万 | 14.94% | | 688363 华熙生物 | -1082.37万 | -5.36% | -412.97万 | -2.04% | 1495.34万 | 7.40% | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | -- ...

Investment Rating - The report maintains an "Outperform" rating for the North Exchange [4] Core Insights - The North Exchange's Specialized, Refined, Unique, and Innovative Index (北证专精特新指数) serves as a new investment benchmark for innovative small and medium-sized enterprises, reflecting the government's strategic intent to enhance the development environment for SMEs and strengthen capital market services [14][17] - The index's total market capitalization reached 238.478 billion, with a 52-week increase of +144.42% as of August 5, 2025, indicating strong performance [14] - The index is designed to provide a diversified asset allocation tool and evaluation benchmark, addressing the lack of investment targets on the North Exchange [20] Summary by Sections Strategic Positioning of the Index - The North Exchange's Specialized, Refined, Unique, and Innovative Index was launched to support the high-quality development of SMEs, reflecting a collaborative effort between the government and exchanges [14][17] - The index includes 50 of the largest specialized and innovative small giant enterprises, with a base point of 1000 as of June 28, 2024 [14] Comparison with Other Specialized Enterprises - The North Exchange's specialized enterprises exhibit characteristics of "medium R&D, high profitability, and stable growth," distinguishing them from other boards [2][39] - The average ROE for the North Exchange is 6.57%, significantly higher than the 3.79% of the Growth Enterprise Market and 2.40% of the Sci-Tech Innovation Board [38][39] - The North Exchange's enterprises are primarily concentrated in mechanical equipment, power equipment, basic chemicals, automotive, and electronics sectors [40] Future Outlook - The North Exchange's index is expected to become a benchmark tool for institutional allocation of innovative small-cap assets, driving the exchange towards a "value discovery market" [3] - The index's dynamic optimization mechanism and policy empowerment are anticipated to enhance resource integration and liquidity [3][21] Index Composition and Rules - The index's component stocks are selected based on strict criteria, ensuring representativeness and investment value, with 49 national-level and 11 provincial-level specialized small giants included [23][27] - The index employs a free-float market capitalization weighting method, allowing larger companies to have a higher influence on the index [27] Industry Distribution - The index focuses on sectors related to new productivity, with mechanical equipment, electronics, power equipment, automotive, and computers representing 30%, 16%, 12%, 8%, and 8% of the listed companies, respectively [35][40]

Group 1 - The medical beauty sector increased by 0.16% on August 6, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3633.99, up 0.45%, while the Shenzhen Component Index closed at 11177.78, up 0.64% [1] - Key stocks in the medical beauty sector showed varied performance, with Jinbo Biological closing at 328.28, up 0.90%, and Aimeike slightly down by 0.03% [1] Group 2 - The medical beauty sector experienced a net outflow of 171.11 thousand yuan from main funds, while retail funds saw a net outflow of 668.85 thousand yuan [1] - The table indicates that *ST Meigu had a main fund inflow of 145.78 thousand yuan but a significant outflow from retail investors [2] - Huaxi Biological and Aimeike also showed mixed fund flows, with Huaxi experiencing a net outflow from main funds and a small inflow from retail investors [2]

Investment Rating - The report suggests a focus on companies in the recombinant collagen sector, highlighting their potential for growth and market leadership [5][6]. Core Insights - Collagen is essential for human health, providing structural support and biological functions [11][14]. - The domestic recombinant collagen technology is advanced, with a complete industrial chain and supportive policies driving growth [6][31]. - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen [6][27]. - The applications of collagen are diverse, including medical aesthetics, skincare, intimate health, and hair health [6][33]. Summary by Sections 1. Collagen as a Vital Component - Collagen constitutes 30%-40% of human protein and is crucial for skin, bones, tendons, and ligaments [11][14]. - There are at least 29 types of collagen in the human body, with types I and III being the most common in the skin [14][15]. 2. Production: Recombinant vs. Animal-Derived Collagen - Recombinant collagen is produced using gene engineering, offering advantages such as no virus risk and better biocompatibility compared to animal-derived collagen [19][26]. - The market for recombinant collagen is expected to reach 286.3 billion yuan in 2023, with a significant growth trajectory [27][28]. 3. Policy Support for Market Development - The regulatory framework for recombinant collagen has been improving, with various guidelines issued since 2021 to standardize the industry [31][32]. 4. Diverse Applications of Recombinant Collagen - **Medical Aesthetics**: The market for recombinant collagen in medical aesthetics is projected to grow from 43 billion yuan in 2023 to 143 billion yuan by 2027, with a CAGR of 35.4% [6][42]. - **Skincare**: The market for functional skincare products containing recombinant collagen is expected to grow from 115 billion yuan in 2023 to 665 billion yuan by 2027, with a CAGR of 54.9% [47][49]. - **Intimate Health**: The market for intimate health products is anticipated to grow significantly, driven by increasing consumer awareness and demand [51][52]. 5. Key Companies in the Industry - **Jinbo Biological**: A leader in recombinant collagen with unique medical aesthetic products [5][40]. - **Juzi Biological**: Known for its brands Kefu Mei and Keli Jin, actively expanding its medical aesthetic pipeline [5][40]. - **Marubi Biological**: Accelerating its research in collagen, with significant product launches [5][40].

证券之星消息，8月5日医疗美容板块较上一交易日上涨0.41%，锦波生物领涨。当日上证指数报收于 3617.6，上涨0.96%。深证成指报收于11106.96，上涨0.59%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净点比 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 271.70万 | 17.26% | -314.88万 | -20.00% | 43.17万 | 2.74% | | 300896 爱美客 | -244.71万 | -0.61% | 2272.19万 | 5.64% | -2027.48万 | -5.04% | | 688363 华熙生物 | -618.47万 | -4.84% | 768.54万 | 6.01% | -150.07万 | -1.17% | 从资金流向上来看，当日医疗美容板块主力资金净流出591.48万元，游资资金净流入2725.85万元，散户 资金净流出2134.38万元。医疗美容板块个股资金流向见下表： ...

证券之星消息，8月4日医疗美容板块较上一交易日下跌0.9%，*ST美谷领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出5284.74万元，游资资金净流入2440.66万元，散户 资金净流入2844.08万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 183.25 | -0.69% | 2.05万 | 3.73 Z | | 832982 | 锦波生物 | 319.85 | -0.95% | 7186.67 | 2.30 Z | | 688363 | 华熙生物 | 51.35 | -1.15% | 2.85万 | 1.46 Z | | 000615 | *ST美谷 | 3.0 ...